Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Optimizing the safety of antibody–drug conjugates for patients with solid tumours is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Optimizing the safety of antibody–drug conjugates for patients with solid tumours have?
Optimizing the safety of antibody–drug conjugates for patients with solid tumours has 243 citations in the OpenAlex counts ScholarIQ stores.
When was Optimizing the safety of antibody–drug conjugates for patients with solid tumours published?
Optimizing the safety of antibody–drug conjugates for patients with solid tumours has 2023 year in the ScholarIQ index.
What is the open-access status of Optimizing the safety of antibody–drug conjugates for patients with solid tumours?
Optimizing the safety of antibody–drug conjugates for patients with solid tumours has bronze oa status in the ScholarIQ index.
What is the DOI of Optimizing the safety of antibody–drug conjugates for patients with solid tumours?
The DOI for Optimizing the safety of antibody–drug conjugates for patients with solid tumours is on the source record.
What is the PMID of Optimizing the safety of antibody–drug conjugates for patients with solid tumours?
The PMID for Optimizing the safety of antibody–drug conjugates for patients with solid tumours is on the source record.
What is the OpenAlex record for Optimizing the safety of antibody–drug conjugates for patients with solid tumours?
The OpenAlex for Optimizing the safety of antibody–drug conjugates for patients with solid tumours is on the source record.